Comparative Pharmacology
Head-to-head clinical analysis: PIMOZIDE versus TARACTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIMOZIDE versus TARACTAN.
PIMOZIDE vs TARACTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Blocks dopamine D2, D3, and D4 receptors; also 5-HT2A, α1-adrenergic, and H1 receptors.
Thioxanthene antipsychotic; blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic system; also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
1-10 mg orally once daily; maximum 10 mg/day.
Oral: 25-50 mg three times daily, increased as needed to 400-600 mg/day. IM: 12.5-25 mg every 6-8 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 50-60 hours in adults; may be prolonged in elderly or hepatic impairment.
Clinical Note
moderatePimozide + Levofloxacin
"Pimozide may increase the QTc-prolonging activities of Levofloxacin."
Clinical Note
moderatePimozide + Norfloxacin
"Pimozide may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderatePimozide + Gemifloxacin
"Pimozide may increase the QTc-prolonging activities of Gemifloxacin."
Clinical Note
moderatePimozide + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Pimozide is combined with Fluticasone propionate."
Terminal elimination half-life is approximately 20-40 hours (mean 30 hours). Steady-state reached in 5-7 days.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 70-90% of eliminated drug; fecal excretion ~10-30%.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Metabolites eliminated renally (30%) and fecally (70%).
Category A/B
Category C
Typical Antipsychotic
Typical Antipsychotic